Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma

University of Wisconsin (UW)

Status and phase: Completed; Phase 2

Conditions: Mantle Cell Lymphoma

Treatments: Drug: modified Hyper-CVAD

Study type: Interventional

Funder types: Other

Identifiers

NCT00581854

HO00401

Details and patient eligibility

About

rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Full description

rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Untreated mantle cell lymphoma

Exclusion criteria

• Pregnant or breast feeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)